SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
SummaryIn the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Thrombotic thrombocytopenic purpura
SummaryThrombotic thrombocytopenic purpura (TTP) is a  clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation. TTP is characterized by a severe deficien cy of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for physiological cleavage of von Willebrand factor (VWF). Organ dysfunction can be severe and life-threatening, and imme...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic breast cancer
SummaryOligometastatic disease characterizes a  distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several cas e series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defen...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Current and evolving treatment strategies in adult immune thrombocytopenia
SummaryImmune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding —which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxic ity associated with treatment may outweigh its benefit. Most patients treated with standard first-line regimen of gl...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept ...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

Report from the ASCO 2018 Congress, Chicago, June 1st-5th, 2018
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Nonmalignant hematology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 25, 2018 Category: Cancer & Oncology Source Type: research

ASCO 2018: highlights of urothelial cancer and prostate cancer
SummaryProstate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year ’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium -223 dose escalation study concluded that the currently used dose with 6 cycles of 55 kBq/kg remains the standard of care. The PARP inhibitor olapar...
Source: Memo - Magazine of European Medical Oncology - July 24, 2018 Category: Cancer & Oncology Source Type: research

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct
We present the case of a  65-year-old woman with sublingual adenoid cystic carcinoma (ACC). Computed tomography (CT) sialography revealed an expansive process in the left sublingual gland accompanied with ipsilateral submandibular salivary duct obstruction. The head and neck tumor board recommended surgical and radiotherap y treatment. Presently, the patient is disease-free with no visible complications or signs of recurrence. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 20, 2018 Category: Cancer & Oncology Source Type: research

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
SummaryPreoperative administration of chemotherapy is a  widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy a llows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes. A multitude of cl...
Source: Memo - Magazine of European Medical Oncology - July 19, 2018 Category: Cancer & Oncology Source Type: research

Demystification of palliative care: what palliative care teams don ’t want you to think about them
SummaryThere is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  2: flow cytometry
SummaryFlow cytometry (FC) plays an important role in the diagnosis and classification of hematological disorders and can analyze a  wide range of diagnostic samples. It is used in both diagnostic and follow-up testing, and is increasingly important in the detection of very small residual disease populations, i. e., minimal residual disease (MRD). Modern flow cytometers have the capability to analyze several thousands of cell s per second and to identify different cell populations by evaluating the expression of specific antigens (markers) along with light scatter properties of the cells. FC can precisely differenti...
Source: Memo - Magazine of European Medical Oncology - June 25, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the management of liver metastases of advanced colorectal cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 14, 2018 Category: Cancer & Oncology Source Type: research

Management of adverse events related to checkpoint inhibition therapy
SummaryIO treatments (immuno-oncology treatments) have become reality and are now daily practice or, in some cases, a daily challenge. New recommendations are being made with the prime purpose of increasing alertness and awareness as well as emphasizing standard operating strategies to deal with immune-related adverse events (ir-AEs) in patients treated with immune checkpoint inhibitors (ICI). This brief review refers to systemic reviews, guidelines and meta-analyses, randomized controlled trials and case series published from 2000 to the present. Existing recommendations for optimal management of toxicities vary according...
Source: Memo - Magazine of European Medical Oncology - June 12, 2018 Category: Cancer & Oncology Source Type: research

Chimeric antigen receptor T ‑cell therapy—a hematological success story
SummaryChimeric antigen receptor (CAR) T  cells are genetically engineered autologous cells that express an activating receptor targeted towards one or more tumoral antigens. Afterex vivo production and re-infusion, they are able to proliferate in the host and to recognize and kill tumor cells. Together with checkpoint inhibition, this new therapy is already being celebrated as a  major medical breakthrough in recent years, due to the substantial benefit observed in clinical trials with patients with chemotherapy-refractory B‑cell malignancies. These results have led to the recent approval of two CAR T‑cell p...
Source: Memo - Magazine of European Medical Oncology - June 6, 2018 Category: Cancer & Oncology Source Type: research

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
SummaryAt the 2017 American Society of Hematology Meeting promising data were presented reflecting the impressing advances of clinical research in multiple myeloma. In fit patients eligible for autologous stem cell transplantation new induction regimens showed high response and minimal residual disease negativity rates. Again the important role of autologous stem cell transplantation was pointed out especially for patients with high risk cytogenetics. In the relapsed setting intensified combination therapies are related with improvement of PFS (progression free survival) and even OS (overall survival). Concerning maintenan...
Source: Memo - Magazine of European Medical Oncology - June 6, 2018 Category: Cancer & Oncology Source Type: research

Chronic lymphocytic leukemia at ASH 2017
SummaryAt ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2018 Category: Cancer & Oncology Source Type: research

Update and clinical highlights presented at the 2017  American Society of Hematology Meeting
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in aggressive Non Hodgkin ’s Lymphoma
SummaryCombined-modality treatment with chemo-immunotherapy and radiotherapy produces excellent outcomes in early-stage, non-bulky diffuse large B ‑cell lymphoma, and reducing toxicity of therapy is a major concern, especially in elderly patients. In a recent trial, elderly patients with non-bulky (
Source: Memo - Magazine of European Medical Oncology - May 28, 2018 Category: Cancer & Oncology Source Type: research

Acute myeloid leukemia —current data from the 2017 American Society of Hematology meeting
SummaryPurposeTo review data on acute myeloid leukemia (AML) presented at the 2017 meeting of the American Society of Hematology (ASH) and to discuss these data within the framework of future developments for the disease.Results and conclusionData generated by next generation sequencing (NGS) may be used for primary diagnosis, therapy selection and monitoring as well as characterization of persons at risk for AML development. After validation, this method will need to be implemented in general practice in the future. For treatment more targeted therapies —single agent or in combination with standard chemotherapy or l...
Source: Memo - Magazine of European Medical Oncology - May 25, 2018 Category: Cancer & Oncology Source Type: research

The adolescence of cancer immunotherapy: from a  difficult childhood to a pillar of modern anticancer therapy
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 24, 2018 Category: Cancer & Oncology Source Type: research

Current and future developments of immunotherapy in lung cancer
This article summarizes the current evidence for ICIs in early and advanced NSCLC as well as in SCLC. Furthermore, current data and ongoing clinical trials on combination therapies are discussed as well as challenges of immunotherapy in lung cancer patients. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 23, 2018 Category: Cancer & Oncology Source Type: research

ASH 2017: highlights in chronic myeloid leukemia
SummaryDespite remarkable achievements in the management of chronic myeloid leukemia (CML), there remain a  number of challenges in the field. At the American Society of Hematology (ASH) Meeting 2017 several presentations addressed current problems around the topics CML stem cells, progression of CML into blast crisis (BC), and personalized treatment. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 23, 2018 Category: Cancer & Oncology Source Type: research

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
SummaryPatients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemotherapy, optimal sequencing of treatments, treatment guidance by means of predictive biomarkers, and value-based judgements of treatments. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 18, 2018 Category: Cancer & Oncology Source Type: research

Post SABCS local therapy and radiology
SummaryThis year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a  personal view of the clinically most relevant data in this respect with the following conclusions: A micrometastasis is no indication for axillary dissection. The number of involved sentinel lymph nodes predicts non-sentinel lymph node metastasis and should be taken into account regarding omittin g axillary dissection. Neoadjuvant chemotherapy reduces the risk of non-sentinel lymph node metastasi...
Source: Memo - Magazine of European Medical Oncology - May 15, 2018 Category: Cancer & Oncology Source Type: research

Pulmonary mass: never judge a  book by its cover
ConclusionLymphomatoid granulomatosis (LYG) is a rare pulmonary disease, which should be included in the differential diagnosis of ‘a pulmonary mass’. This case emphasizes the need for tissue acquisition. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 23, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  1: Bone marrow diagnostics in hemato-oncological diseases
SummaryProliferation or reduction of one or more cell lines in the peripheral blood count, occurrence of cells not normally found in the peripheral blood (e.g., blast cells, red precursors), suspicious laboratory findings (e.g., paraproteins, free light chains), lymphadenopathy of unclear origin, or other clinical signs (e.g., fever, B ‑symptoms, bone pain) are indicators of hematologic disease.The following methods can be used either to establish a  diagnosis or to suspect a diagnosis even based on analysis of peripheral blood: cytological cell differentiation, interpretation of cell morphology, laboratory dia...
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Hemoglobinopathies —genetically diverse, clinically complex, and globally relevant
SummaryHemoglobinopathies represent the most frequent monogenic disorders worldwide. Migration during recent years led to a  profoundly increasing number of patients in countries where the indigenous population has not been affected. This short review will give an overview on etiology, pathogenesis, clinical features, diagnostics, and treatment of the most relevant hemoglobinopathies, i.e., the thalassemias and sickle c ell disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Laboratory diagnostics in hematology —a new “Educational” series
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 13, 2018 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 27, 2018 Category: Cancer & Oncology Source Type: research

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms
SummaryPhiladelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by mutations in genes, such asJAK2V617F,JAK2 exon12 gene andMPL. With respect to MPN-associated subclasses, each of these disorders has a  different allele burden during disease treatment. Up to now, several studies have been conducted on the relationship between allele burden with specific MPN-associated phenotypic features, prognosis and disease progression. It seems that finding such a correlation would be a great ...
Source: Memo - Magazine of European Medical Oncology - March 22, 2018 Category: Cancer & Oncology Source Type: research

Pitfalls in the radiological response  assessment of immunotherapy
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - March 21, 2018 Category: Cancer & Oncology Source Type: research

Indolent lymphoma at ASH (American Society of Hematology) 2017: maintenance revisited
SummaryAt the last ASH (American Society of Hematology) meeting a  new prognostic tool for follicular lymphoma (FL), based on the patient cohort of the PRIMA trial (PRIMA-PI, Primary Rituximab and Maintenance-Prognostic Index), was presented. The 10-year update of the PRIMA trial confirms the continuous advantage in progression-free survival of rituximab maintena nce after R‑CHOP induction without new safety signals. Similarly rituximab maintenance is beneficial in FL after first-line chemoimmunotherapy with rituximab–bendamustine. Currently checkpoint inhibitors are under investigation in different treatment ...
Source: Memo - Magazine of European Medical Oncology - March 21, 2018 Category: Cancer & Oncology Source Type: research

PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients
SummaryUntil recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained diseas...
Source: Memo - Magazine of European Medical Oncology - March 8, 2018 Category: Cancer & Oncology Source Type: research

In need of special care: adolescent and young adult patients with cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 2, 2018 Category: Cancer & Oncology Source Type: research

APPLY: A  prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
In this study, 497 patients with a  mean age of 60.6 years were analyzed. Most patients (80.7%) were initiated on darbepoetin alfa at a Hb of 9–11 g/dL, congruent with recommendations. The median Hb increased by 0.9 g/dL between baseline and week 12. Hb target achievement was higher among patients treated according to guidel ines than those initiated at Hb 
Source: Memo - Magazine of European Medical Oncology - March 2, 2018 Category: Cancer & Oncology Source Type: research

Revival of anti-angiogenic therapies in cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 27, 2018 Category: Cancer & Oncology Source Type: research

Targeting angiogenesis in lung cancer
SummaryAngiogenesis inhibition is a  promising way to inhibit and eradicate cancer. Many attempts have been made to use this tool for the treatment of lung cancer. Some success has been reported, and antiangiogenic drugs are actively being investigated in combination with other types of anticancer treatments. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Antiangiogenic therapies in ovarian cancer
SummaryAntiangiogenic compounds were the first active targeted agents implemented in the treatment of ovarian cancer. Bevacizumab and tyrosine kinase inhibitors such as pazopanib, nintedanib and cediranib target the VEGF pathway, while trebananib was developed as an inhibitor of the angiopoietin pathway. All these compounds have been extensively evaluated and, in this review, we provide a  structured overview of the randomized trials that have been performed in both primary and relapsed ovarian cancer. From this data, it is evident that antiangiogenic therapy has its place in ovarian cancer. If not during first-line t...
Source: Memo - Magazine of European Medical Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer
SummaryThe STAMPEDE and CHAARTED trials brought about practice-changing innovation in the management of patients with metastatic, castration-naive prostate cancer (CNPC). These trials reported a  clinically meaningful overall survival benefit of chemohormonal therapy consisting of the addition of six cycles of docetaxel to androgen deprivation therapy (ADT) in high-volume metastatic CNPC. Moreover, the STAMPEDE study also transformed our thinking about conducting clinical trials through it s adaptive, multigroup, multistage trial design. With the recent results of the LATITUDE trial and publication of another STAMPEDE...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
ConclusionPleural effusion carries a  differential diagnosis which may include malignancy but is commonly thought to be less specific to multiple myeloma but should still remain in the differential diagnosis. To our knowledge, this is the first case of myelomatous pleural effusion (MPE) that was reported after multiple relapses of MM. MPE is a very rare complication of MM, and its presence is a strong indicator of imminent mortality and need for comfort care in case of multiple relapses. End-stage pleural effusion in MM in the setting of proteasome inhibitor adds more therapeutic and diagnostic challenges. (...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
SummaryThe treatment of newly diagnosed multiple myeloma has changed dramatically over the past 20  years, from near uniform application of chemotherapy to a patient performance status- and risk-based approach. Furthermore, initiation of treatment criteria have evolved from a pure end-organ damage-based definition to include risk factors of transformation to frank myeloma. Besides, the mainly cytogenetically defined Multiple Myeloma (MM) risk status, transplant eligibility of patients still serves primarily to allocate patients within a rational treatment algorithm.While all transplant-eligible MM patie...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood
SummarySurvival after childhood cancer has improved substantially; therefore, the number of childhood cancer survivors is increasing. This growing population of childhood cancer survivors, however, is at risk of a  spectrum of adverse health outcomes. Unfortunately, until now, there was a lack of comprehensive follow-up recommendations. The purpose of this article is to provide information on recently developed harmonized evidence-based guidelines on surveillance investigations to screen for the early detec tion of breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian failure in childhood canc...
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017
Correction to:memo 2017https://doi.org/10.1007/s12254-017-0381-xUnfortunately, the title of this article was published incorrect.The correct title is: Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017.The original article has been … (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 21, 2018 Category: Cancer & Oncology Source Type: research

ESMO 2017 —my personal highlights
This article is not intended to be a  comprehensive review of all highlights presented at the recent ESMO Annual Meeting, but rather a summary from a personal point of view in three very different fields of oncology. Breast cancer and lung cancer are traditionally in the focus of interest, and again, relevant new data were presented . The third part of this overview is focused on novel treatment strategies in malignant lymphoma, a field that is also quickly evolving and traditionally underrepresented at meetings dealing with solid cancers. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 16, 2018 Category: Cancer & Oncology Source Type: research

Anti-angiogenic therapies in  brain metastases
SummaryBrain metastases are a  major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising prevent ive as well as therapeutic approach. The current review will summarize the current available data on the efficacy of neo-angiogenic therapies in patients with brain metastases. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 2, 2018 Category: Cancer & Oncology Source Type: research

Role of complement in the pathogenesis of thrombotic microangiopathies
SummaryThrombotic microangiopathies (TMAs) are rare but life-threatening disorders characterized by microvascular hemolytic anemia and acute thrombocytopenia with or without organ damage. The term TMA covers various subgroups of diseases, the pathogenesis of which is briefly summarized in this review. As highlighted here, complement activation may represent an important amalgamating process in all of these conditions, since it is able to link together activation and damage of multiple involved cell types, such as endothelial cells, platelets, and neutrophils. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 17, 2018 Category: Cancer & Oncology Source Type: research

Report from the WCLC 2017 Congress, Yokohama, 15th –18th October, 2017
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 8, 2018 Category: Cancer & Oncology Source Type: research